Lv6
2296 积分 2024-11-19 加入
Adverse cardiac events associated with antibody-drug conjugates in cancer patients: retrospective analysis of FAERS database and RCTs
4个月前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
4个月前
已完结
Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment
4个月前
已关闭
Antibody-Drug Conjugates in urothelial, prostate, and renal cell cancers: A review of current and emerging therapies
4个月前
已完结
Study design and rationale for the NeoTRACE trial: a multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer
4个月前
已完结
Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity
4个月前
已完结
Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives
4个月前
已完结
GPC-3 in hepatocellular carcinoma; A novel biomarker and molecular target
5个月前
已完结
Antibody-drug conjugates for hepato-pancreato-biliary malignancies: "Magic bullets" to the rescue?
5个月前
已完结
Targeting glypican 3 by immunotoxins: the promise of immunotherapy in hepatocellular carcinoma
5个月前
已完结
皖公网安备34019202002308
